VGTI researchers receive $12.6 million to study West Nile virus in the elderly

October 11, 2005

PORTLAND, Ore. -- Researchers at the Oregon Health & Science University Vaccine and Gene Therapy Institute (VGTI) have received a $12.6 million grant from the federal government to assist in efforts to better protect the elderly against West Nile virus and related diseases. The grant is funded by the National Institute of Allergy and Infectious Disease, a component of the National Institutes of Health.

West Nile virus is a seasonal epidemic that occurs throughout the summer months. Typically, the disease is carried from animals to humans by mosquitoes. As many as 20 percent of humans who are infected may display symptoms. However only less than 1 percent of those infected will become seriously ill. For serious cases, symptoms can include high fever, coma, tremors and paralysis. In some cases, the disease can cause permanent neurological impacts or be fatal.

"What's particularly concerning about this disease is the fact that serious illness is much more common in those older than 50," explained Janko Nikolich-Zugich, Ph.D., a senior scientist at the VGTI. "We have little understanding as to why this is the case. Increased knowledge about this population's susceptibility may lead us to new methods for protecting these people and also others who may become infected. In addition, lessons learned from West Nile studies will likely assist in the battle against other related Flaviviruses such as dengue virus, Japanese encephalitis virus and yellow fever virus, as well as organisms used for bioterrorism "

A combination of studies in older animals and humans will be used to determine the best possible models for future studies of the disease and the development of new human treatments and a human vaccine.

In both humans and animals, scientists will track immune system responses to West Nile. These studies will include observations of the disease's impacts on the two major components of the immune system: the innate (macrophages) and adaptive immune responses (T and B cells). Through these studies, scientists hope to determine the specific factors that increase susceptibility to West Nile virus.

"We would like to find out what in us deteriorates with age allowing the virus to have a greater ability to create serious illness.," explained Nikolich-Zugich.

The scientists and their colleagues also believe the findings of this research may have commercial impacts that benefit Oregonians.

"Once we understand the mechanisms and identify therapy targets associated with innate and adaptive immunity to West Nile virus, OHSU would welcome the opportunity to partner with industry and develop therapeutic approaches for WNV as well as other flaviviruses," said Arundeep Pradhan, OHSU's director of Technology and Research Collaborations.

"This grant award will accelerate the further development and eventual commercialization of a new drug candidate," said Al Ferro, Ph.D., Chairman of Virogenomics Inc. Virogenomics is an Oregon-based biotechnology company that has been working with the VGTI to develop novel therapeutics against WNV with promising results.

Other VGTI scientists involved in the research are: Jay Nelson, Ph.D., director of the VGTI; Klaus Frueh, Ph.D.; Ashlee Moses, Ph.D.; Scott Wong, Ph.D.; and Mike Axthelm, Ph.D. Researchers at OHSU will also collaborate with scientists at Tulane University, the University of Pittsburgh and the University of Texas branches in Galveston and Houston.
-end-
Particulars:
Janko Nikolich-Zugich, Ph.D., is a professor of molecular microbiology and immunology in the OHSU School of Medicine; and senior scientist at the OHSU Vaccine and Gene Therapy Institute and the Oregon National Primate Research Center.

Oregon Health & Science University

Related West Nile Virus Articles from Brightsurf:

Rising temperatures could shift US West Nile virus transmission
West Nile virus spreads most efficiently in the US at temperatures between 24-25 degrees Celsius (75.2-77 degrees Fahrenheit), a new study published today in eLife shows.

West Nile virus triggers brain inflammation by inhibiting protein degradation
West Nile virus (WNV) inhibits autophagy -- an essential system that digests or removes cellular constituents such as proteins -- to induce the aggregation of proteins in infected cells, triggering cell death and brain inflammation (encephalitis), according to Hokkaido University researchers.

WSU study shows insulin can increase mosquitoes' immunity to West Nile virus
A discovery by a Washington State University-led research team has the potential to inhibit the spread of West Nile virus as well as Zika and dengue viruses.

Critical protein that could unlock West Nile/Zika virus treatments identified
A team of Georgia State scientists has identified a protein that is critical in controlling replication of West Nile and Zika viruses -- and could be important for developing therapies to prevent and treat those viruses.

West Nile virus in the New World: Reflections on 20 years in pursuit of an elusive foe
Though eradication of West Nile virus remains beyond our capability, the body of knowledge built since its arrival in the Americas in 1999 is now powering efforts to minimize its impact and prepare for the invasion of other mosquito-borne diseases.

Light pollution may be increasing West Nile virus spillover from wild birds
House sparrows infected with West Nile virus (WNV) that live in light polluted conditions remain infectious for two days longer than those who do not, increasing the potential for a WNV outbreak by about 41%.

Mount Sinai researchers find significant delays in West Nile virus reporting
Mount Sinai researchers found significant delays in reporting human cases of West Nile virus, hampering real-time forecasting of the potentially deadly mosquito-borne disease, according to a study in the JAMA Network Open in April.

Insecticide resistance genes affect vector competence for West Nile virus
In a context of overuse of insecticides, which leads to the selection of resistant mosquitoes, it is already known that this resistance to insecticides affects interactions between mosquitoes and the pathogens they transmit.

Where will the world's next Zika, West Nile or Dengue virus come from?
Scientists from the University of California, Davis, have identified wildlife species that are the most likely to host flaviviruses such as Zika, West Nile, dengue and yellow fever.

Vanderbilt discovery could neutralize West Nile virus
Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can 'neutralize' the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.

Read More: West Nile Virus News and West Nile Virus Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.